Share
     
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
11:00
MOAB0101
Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1-infected adults with tuberculosis: W48 results of the ANRS 12300 Reflate TB2 trial
Nathalie De Castro, APHP- Hopital Saint Louis, France
Abstract
Slides
11:15
MOAB0102
Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study)
Max Lataillade, ViiV Healthcare, United States
Abstract
11:30
MOAB0103
Patient views on long acting HIV treatment: Cabotegravir + rilpivirine as maintenance therapy (ATLAS 48 week results)
Miranda Murray, ViiV Healthcare, United Kingdom
Abstract
Slides
11:45
MOAB0104
Virologic failure In ART-naive HIV patients with high pre-therapy viral load burden initiating on common core agents
Anthony M Mills, Men’s Health Foundation, United States
Abstract
Slides
11:55
MOAB0105
Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
Paul E. Sax, Brigham and Women's Hospital, Harvard Medical School, United States
Abstract
Slides
12:10
MOAB0106
Longer-term (96-week) efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in women
Cissy Kityo, Joint Clinical Research Centre, Uganda
Abstract
Slides
AUTHOR
SUMMARY
HIGHLIGHTS
CRITICAL ASSESSMENT